|
| 產(chǎn)地 | France |
| 品牌 | AntibodySystem |
| 保存條件 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -350°C long term. |
| 貨號(hào) | DVV02803 |
| 用途 | 類似物，陽(yáng)性對(duì)照抗體 |
| 應(yīng)用范圍 | 類似物，陽(yáng)性對(duì)照抗體 |
| 抗原來(lái)源 | Mammalian cells |
| 保質(zhì)期 | 1 year |
| 抗體名 | Research Grade Motavizumab |
| 是否單克隆 | 是 |
| 克隆性 | 是 |
| 靶點(diǎn) | MEDI-524 |
| 適應(yīng)物種 | Human |
| 形態(tài) | Liquid |
| 宿主 | 是 |
| 標(biāo)記物 | Unconjugate |
| 包裝規(guī)格 | 100ug |
| 亞型 | IgG |
| 標(biāo)識(shí)物 | Unconjugate |
| 濃度 | 1mg/ml% |
| 免疫原 | Human |
| 是否進(jìn)口 | 是 |
Tags: Motavizumab ( 莫維組單抗 ) supplier,Motavizumab ( 莫維組單抗 ) purchase,Motavizumab ( 莫維組單抗 ) manufacturer,Motavizumab ( 莫維組單抗 ) distributor,Motavizumab ( 莫維組單抗 ) cost,Motavizumab ( 莫維組單抗 ) buy,Motavizumab ( 莫維組單抗 ) for sale
Motavizumab (MEDI-524, NUMAX, NISTmAb) is a second generation monoclonal antibody (mAb) derived from palivizumab (Synagis) using affinity maturation techniques. Motavizumab is currently undergoing US Food and Drug Administration review as a treatment for respiratory syncytial virus (RSV) prophylaxis.
It has been evaluated in large-scale clinical studies, and has demonstrated efficacy in reducing the disease burden of RSV in high-risk infant populations.Motavizumab (MEDI-524, NUMAX, NISTmAb) has higher affinity and a longer half-life, was effective in reducing RSV hospitalization in high-risk full-term infants in the US, but was not licensed due to safety concerns (allergic reactions) .
DVV02803
Humanized
HRSV-A
Liquid
0.01M PBS, pH 7.4.
1.36 mg/ml
>95% by SDS-PAGE.
Monoclonal
IgG1, kappa
Research Grade Motavizumab Biosimilar
F,Fusion glycoprotein F0
Protein A or G purified from cell culture supernatant.
Please contact with the lab for this information.
Mammalian
P03420
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
MEDI-524,NUMAX, NISTmAb, CR9503, CAS: 677010-34-3, Human Respiratory Syncytial Virus (HRSV)
For research use only. Not suitable for clinical or therapeutic use.
Aiming to develop the most reliable bioreagents, AntibodySystem SAS was founded in 2019 in France by a team of professionals from top industrial companies and research institutes. The collective scientific and technical experiences in our team have brought breaking throughs in multiple product developments, including recombinant antibodies, recombinant proteins, biosimilar, RUO ELISA kits and other related products. By working with talented researchers and technicians, AntibodySystem continues to upgrade product qualities and lower the overall cost, offering accountable and affordable solutions for biolabs all over the world. Since its establishment, AntibodySystem has built long term and stable collaborations with academia, pharmaceutical industry, biotech companies and research hospitals, supporting their R&D by AntibodySystem's bioreagents with excellent data accuracy and reproducibility.
AntibodySystem由具有30多年蛋白抗體開(kāi)發(fā)經(jīng)驗(yàn)的 創(chuàng)立于法國(guó),專注于生命科學(xué)和生物制藥領(lǐng)域研究,總部位于法國(guó)斯特拉斯堡市。AntibodySystem自主開(kāi)發(fā)了高效、高產(chǎn)的真核重組表達(dá)系統(tǒng),利用該系統(tǒng)生產(chǎn)了高質(zhì)量的重組蛋白、抗體產(chǎn)品。目前產(chǎn)品包括藥物靶點(diǎn)蛋白以及對(duì)照抗體藥物、Invivo功能性抗體、SAA系列流式抗體、PEG抗體、磷酸化抗體、抗小分子抗體、ADA抗體、PK&ADA ELISA試劑盒。
普健生物作為AntibodySystem在亞洲區(qū)授權(quán) ,致力于為廣大科研工作者提供 的產(chǎn)品服務(wù)。
如果您對(duì)我們的產(chǎn)品感興趣,請(qǐng)聯(lián)系027-65279366。
以上產(chǎn)品僅用于科研,產(chǎn)品信息以產(chǎn)品 為準(zhǔn)
